Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Hassan Javanbakht

Søren Ottosen

Lykke Pedersen

Song Yang

Xingchun Han

Yongguang Wang

Souphalone Luangsay

Malene Jackerott

Chungen Liang

Jianping Wang

Min Jiang

Robert James Weikert

Chengang Zhou

Henrik Mueller

Zhanguo Wang

Morten Lindow

Soren Ottosen

The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and/or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.

Oligomers and oligomer conjugates

A method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection is provided, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. Inhibitors of PAPD5 or PAPD7 are provided for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection.

Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection

The present invention relates to antisense oligonucleotides that are capable of reducing expression of PD-L1 in a target cell. The oligonucleotides hybridize to PD-L1 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of viral liver infections such as HBV, HCV and HDV; parasite infections such as malaria, toxoplasmosis, leishmaniasis and trypanosomiasis or liver cancer or metastases in the liver using the oligonucleotide.

Oligonucleotides for reduction of PD-L1 expression

The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for an inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a 10 pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.

PAPD5 and PAPD7 inhibitors for treating a hepatitis B infection

The invention provides novel compounds having the general formula: wherein R, R, R, R, Rand Rare as described herein, compositions including the compounds and methods of using the compounds.

Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection

Growing community of inventors

Basel, Switzerland

Hassan Javanbakht